ABBV 621

Drug Profile

ABBV 621

Alternative Names: ABBV-621

Latest Information Update: 27 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AbbVie
  • Class Antineoplastics; Proteins
  • Mechanism of Action TNF-related apoptosis-inducing ligand receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 20 Mar 2017 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater) in USA (IV) (NCT03082209)
  • 20 Mar 2017 Phase-I clinical trials in Solid tumours (Second-line therapy or greater) in USA (IV) (NCT03082209)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top